Evidence/Findings:
Based on record review and interview, the manager failed to ensure that a medication administered to a resident was documented in the resident's medical record, for two of four residents sampled. The deficient practice posed a risk as medication could not be verified as administered against a medication order.
Findings include:
1. A review of R1's medical record revealed R1 received medication administration.
2. A review of R1's medical record revealed a medication list, dated January 8, 2025, that included the following medications:
- Acetaminophen 500 milligrams (mg), 2 tablets by mouth (po) three times a day (tid);
- Amlodipine 5 mg, 1 tablet po at bedtime (qhs);
- Gabapentin 100 mg, 2 capsules po tid;
- Gabapentin 400 mg, 1 capsule po qhs;
- Metformin 500 mg, 2 tablet po twice a day (bid);
- Tramadol HCL 50 mg, 1 tablet po tid; and
- Trazodone HCL 100 mg, 2 tablets po qhs.
3. A review of R1's medication administration record (MAR) for January 2025 revealed missing documentation of the following medications, on the following dates:
- Acetaminophen 500 mg, at 8:00 PM on January 11, 2025, January 24, 2025, and January 25, 2025;
- Amlodipine 5 mg, at 8:00 PM on January 24, 2025 and January 25, 2025;
- Gabapentin 100 mg, at 2:00 PM on January 29, 2025;
- Gabapentin 400 mg, at 8:00 PM on January 11, 2025, January 24, 2025, and January 25, 2025;
- Metformin 500 mg, at 8:00 PM on January 24, 2025 and January 25, 2025;
- Tramadol HCL 50 mg, at 8:00 PM on January 24, 2025 and January 25, 2025; and
- Trazodone HCL 100 mg, at 8:00 PM on January 11, 2025, January 24, 2025, and January 25, 2025.
4. A review of R2's medical record revealed R2 received medication administration.
5. A review of R2's medical record revealed a medication list, dated January 15, 2025, that included the following medications:
- Advair Diskus 250 - 50 micrograms (MCG), 1 inhale every 12 hours (q12h);
- Atorvastatin Calcium 40 mg, 1 tablet po qhs;
- Carbidopa-Levodopa 25-250 mg, 1 tablet po tid;
- Quetiapine Fumarate 25 mg, 1 tablet po at 1:00 PM, 6:00pm, and qhs;
- Rivastigmine Tartrate 4.5 mg, 1 capsule po bid; and
- Senna 8.6 mg, 1 tablet po qd.
6. A review of R2's MAR for January 2025, revealed missing documentation of the following medications, on the following dates:
- Advair Diskus 250 - 50 mcg, at 8:00 PM on January 11, 2025, January 24, 2025, and January 25, 2025;
- Atorvastatin Calcium 40 mg, at 8:00 PM on January 11, 2025;
- Carbidopa-Levodopa 25-250 mg, at 12:00 PM on January 29, 2025;
- Quetiapine Fumarate 25 mg, at 8:00 PM on January 11, 2025, January 24, 2025, and January 25, 2025;
- Quetiapine Fumarate 25 mg, at 1:00 PM on January 29, 2025; and
- Rivastigmine Tartrate 4.5 mg, at 8:00 PM on January 11, 2025, January 24, 2025, and January 25, 2025.
7. In an interview, E1 reported R1 and R2 received all aforementioned medications at the required times; however, documentation of the administration was not available for review. E1 acknowledged R1's and R2's medical records did not include documentation of each medication administered to the residents.
Summary:
UPDATED ON JUNE 24, 2025
The following deficiencies were found during the on-site investigation of complaints 00130574 and 00130600 conducted on May 14, 2025: